BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24468978)

  • 21. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
    Walts AE; Mirocha JM; Bose S
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.
    Yip L; Nikiforova MN; Yoo JY; McCoy KL; Stang MT; Armstrong MJ; Nicholson KJ; Ohori NP; Coyne C; Hodak SP; Ferris RL; LeBeau SO; Nikiforov YE; Carty SE
    Ann Surg; 2015 Sep; 262(3):519-25; discussion 524-5. PubMed ID: 26258321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.
    Lim JY; Hong SW; Lee YS; Kim BW; Park CS; Chang HS; Cho JY
    Thyroid; 2013 Nov; 23(11):1423-30. PubMed ID: 23496275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.
    Xu B; Serrette R; Tuttle RM; Alzumaili B; Ganly I; Katabi N; Tallini G; Ghossein R
    Thyroid; 2019 Dec; 29(12):1792-1803. PubMed ID: 31452453
    [No Abstract]   [Full Text] [Related]  

  • 27. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size.
    So YK; Son YI; Park JY; Baek CH; Jeong HS; Chung MK
    Otolaryngol Head Neck Surg; 2011 Sep; 145(3):422-7. PubMed ID: 21750338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
    Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
    Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mutation panel comprising BRAF
    Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
    Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.
    Cañadas-Garre M; Becerra-Massare P; Moreno Casares A; Calleja-Hernández MÁ; Llamas-Elvira JM
    Head Neck; 2016 Dec; 38(12):1772-1779. PubMed ID: 27299298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0].
    Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
    Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
    Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear morphometric findings in undetermined cytology: A possible clue for prediction of BRAF mutation in papillary thyroid carcinomas.
    Mungan S; Ersoz S; Saygin I; Sagnak Z; Cobanoglu U
    Endocr Res; 2017 May; 42(2):138-144. PubMed ID: 27911099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
    Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
    JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
    Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.